Janet Vergis

Janet Vergis earned a B.S. degree in Biology and an M.S. degree in Physiology from The Pennsylvania State University.

She has over 35 years of experience in the healthcare industry and served from 2013 to 2019 as an executive advisor to various private equity firms, including, Warburg Pincus, Deerfield Mgmt., Water Street Healthcare Partners and Vatera Healthcare Partners.

From 2011 to 2012, she served as the Chief Executive Officer of OraPharma, Inc., a specialty pharmaceutical company. In that role she led the turnaround of the business and its subsequent successful sale.

Preceding her role at OraPharma, Ms. Vergis managed a multi-billion portfolio at Johnson & Johnson (NYSE: JNJ) as President of Janssen Pharmaceutica, McNeil Pediatrics, and Ortho-McNeil Neurologic. Ms. Vergis contributed to a number of Johnson & Johnson companies during her career, serving as a member of company management boards for over a decade and holding positions of increasing responsibility in research and development, new product development, sales, and marketing.

She previously served on the boards of MedDay Pharmaceuticals, Amneal Pharmaceutical (NYSE:AMRX), Lumara Health, and OraPharma, Inc.